Concepedia

Samuel McNeely

SM

24

Publications

1K

Citations

19

H-Index

1978

Active since

Affiliations

Eli Lilly (United States)(Current)

University of Louisville

Memorial Sloan Kettering Cancer Center

Sarah Cannon

The University of Texas MD Anderson Cancer Center

Samuel McNeely is an author at Eli Lilly (United States) specializing in medicine, cell signaling, and cell biology.

Top concepts

Publications per year

1978–2024

24

Publications

24

LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent Mechanisms

Constance King, H. Bruce Diaz, Samuel McNeely et al. · Molecular Cancer Therapeutics · 2015 · 183 citations · Full text

, , +18

Chk1 inhibition after replicative stress activates a double strand break response mediated by ATM and DNA-dependent protein kinase

Samuel McNeely, Chiara Conti, Tahir Sheikh et al. · Cell Cycle · 2010 · 98 citations · Full text

Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study

Juan W. Valle, Arndt Vogel, Crystal S. Denlinger et al. · The Lancet Oncology · 2021 · 64 citations

, , +5

A Phase 2 study of prexasertib (LY2606368) in platinum resistant or refractory recurrent ovarian cancer

Panagiotis A. Konstantinopoulos, Jungmin Lee, Bo Gao et al. · Gynecologic Oncology · 2022 · 63 citations · Full text

The Checkpoint Kinase Inhibitor AZD7762 Potentiates Chemotherapy-Induced Apoptosis of <i>p53</i> -Mutated Multiple Myeloma Cells

Heather Landau, Samuel McNeely, Jayasree S. Nair et al. · Molecular Cancer Therapeutics · 2012 · 57 citations

Rows per page

1–5 of 24